Perimeter Unveils FDA-Approved AI Imaging System for Breast Cancer Surgery

Event summary

  • Perimeter Medical Imaging AI unveiled Claire™ OCT+AI at the ASBrS 2026 conference, April 29-May 3 in Seattle.
  • Claire received FDA premarket approval in March 2026, the first AI-enabled imaging device approved for intraoperative breast cancer margin assessment.
  • The system combines AI with wide-field OCT imaging, offering 10x higher resolution than standard X-ray and ultrasound at 2mm depth.
  • Claire's AI was trained on a proprietary library of over 2 million breast tissue images.
  • Perimeter aims to reduce repeat surgeries by enhancing real-time tumor margin detection during breast-conserving surgery.

The big picture

Perimeter's FDA approval positions Claire as a potential disruptor in intraoperative breast cancer assessment, addressing a critical unmet need for real-time margin evaluation. The technology could reshape surgical decision-making if it delivers on its promise of higher precision and reduced repeat procedures. The company now faces the challenge of scaling commercial adoption while navigating the complexities of AI-driven medical device regulation.

What we're watching

Adoption Pace
How quickly surgeons will integrate Claire into breast-conserving surgery workflows.
Clinical Impact
Whether the system can demonstrably reduce re-operation rates in real-world settings.
Market Expansion
The pace at which Perimeter can expand Claire's use beyond its current FDA-approved indications.